Matinas BioPharma nominates Kathryn Penkus Corzo to board; LePore not standing for re-election

Matinas BioPharma Holdings, Inc.

Patrick LePore will not stand for re-election at the 2021 Annual Meeting on November 1, 2021.
Kathryn Penkus Corzo nominated to stand for election to the Board at the same meeting.
Corzo is a partner at Takeda Ventures and formerly Head of Oncology Cell Therapy Development at Takeda.
LePore served as Vice Chairman and was thanked for his three years of service.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Patrick LePore

Director

MTNB · Matinas BioPharma Holdings, Inc.

Effective: 2021-11-01
Filed: September 20, 2021, 7:59 PM ET

On September 17, 2021, director Patrick LePore informed the Board of Directors (the “Board”) of Matinas BioPharma Holdings, Inc. (the “Company”) that he will not stand for re-election to the Board at the upcoming annual meeting of stockholders, which will be held on November 1, 2021 (the “Annual Meeting”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Patrick LePore resigned as Director at Matinas BioPharma Holdings, Inc..

Action: resigned
Role: Director

Exact text from the filing

On September 17, 2021, director Patrick LePore informed the Board of Directors (the “Board”) of Matinas BioPharma Holdings, Inc. (the “Company”) that he will not stand for re-election to the Board at the upcoming annual meeting of stockholders, which will be held on November 1, 2021 (the “Annual Meeting”).

View on SEC.gov

Matinas BioPharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-21-023087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.